On the hunt for a bet­ter an­ti­body, BigHat Bio­sciences de­buts with $19M Se­ries A to scale its 'wet lab' AI plat­form

Next-gen an­ti­bod­ies have be­come some­what of a Holy Grail in the drug de­vel­op­ment world, but the process of ac­tu­al­ly cre­at­ing those an­ti­bod­ies has proven to be dif­fi­cult and time con­sum­ing. A brand-new Cal­i­for­nia out­fit is look­ing to solve that time crunch by bring­ing AI and ma­chine learn­ing in­to the lab.

BigHat Bio­sciences de­buted Wednes­day with a $19 mil­lion Se­ries A round to help scale up its “wet lab” AI and ma­chine learn­ing plat­form to speed de­vel­op­ment of next-gen an­ti­bod­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER